Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782909 | 0.89 | HPGD (0.72) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL3245222 | 0.88 | SMPD1 (0.67) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL22015271 | 0.87 | LMNA (0.62) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL30102539 | 0.86 | LMNA (0.76) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL2063068 | 0.86 | SMN1; SMN2 (0.73) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL31241237 | 0.86 | LMNA (0.59) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL4874871 | 0.86 | LMNA (0.76) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL16929834 | 0.86 | LMNA (0.59) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL2188210 | 0.86 | SMPD1 (0.76) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL30809647 | 0.85 | LMNA (0.64) | HPGDLMNASMPD1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2022-01-13 | — | — | US | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2021-08-12 | — | — | US | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805216-A1 | COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246126-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | SLC10A1, GYS2, CPT1A | HPGD 254/4885LMNA 995/4885SMPD1 1078/4885 |
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | PC, PCCA, GLS2 | HPGD 421/4885LMNA 3457/4885SMPD1 1068/4885 |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | HPGD 254/4885LMNA 995/4885SMPD1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.